Buy Or Sell Opportunity • 6h
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 10% to €8.95. The fair value is estimated to be €7.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.6% over the last 3 years. Earnings per share has grown by 26%. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings are also forecast to grow by 16% per annum over the same time period. Duyuru • Jun 03
Nipro Corporation to Report Q1, 2027 Results on Aug 10, 2026 Nipro Corporation announced that they will report Q1, 2027 results on Aug 10, 2026 Duyuru • May 12
Nipro Corporation, Annual General Meeting, Jun 26, 2026 Nipro Corporation, Annual General Meeting, Jun 26, 2026. Duyuru • Mar 09
Nipro Corporation to Report Fiscal Year 2026 Final Results on May 12, 2026 Nipro Corporation announced that they will report fiscal year 2026 final results on May 12, 2026 Duyuru • Dec 17
Nipro Corporation to Report Q3, 2026 Results on Feb 09, 2026 Nipro Corporation announced that they will report Q3, 2026 results on Feb 09, 2026 Duyuru • Sep 30
Nipro Corporation to Report Q2, 2026 Results on Nov 10, 2025 Nipro Corporation announced that they will report Q2, 2026 results on Nov 10, 2025 Duyuru • Jun 03
Nipro Corporation to Report Q1, 2026 Results on Aug 08, 2025 Nipro Corporation announced that they will report Q1, 2026 results on Aug 08, 2025 Duyuru • Mar 04
Nipro Corporation to Report Fiscal Year 2025 Results on May 12, 2025 Nipro Corporation announced that they will report fiscal year 2025 results at 12:00 PM, Tokyo Standard Time on May 12, 2025 Duyuru • Dec 03
Nipro Corporation to Report Q3, 2025 Results on Feb 07, 2025 Nipro Corporation announced that they will report Q3, 2025 results on Feb 07, 2025 Reported Earnings • Nov 10
Second quarter 2025 earnings released: JP¥15.31 loss per share (vs JP¥35.76 profit in 2Q 2024) Second quarter 2025 results: JP¥15.31 loss per share (down from JP¥35.76 profit in 2Q 2024). Revenue: JP¥159.6b (up 9.9% from 2Q 2024). Net loss: JP¥2.50b (down 143% from profit in 2Q 2024). Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Sep 20
Upcoming dividend of JP¥12.00 per share Eligible shareholders must have bought the stock before 27 September 2024. Payment date: 04 December 2024. Payout ratio is a comfortable 42% but the company is not cash flow positive. Trailing yield: 2.4%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (1.9%). Duyuru • Aug 29
Nipro Corporation to Report Q2, 2025 Results on Nov 08, 2024 Nipro Corporation announced that they will report Q2, 2025 results on Nov 08, 2024 Buy Or Sell Opportunity • Aug 06
Now 22% overvalued Over the last 90 days, the stock has fallen 2.7% to €7.15. The fair value is estimated to be €5.88, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.8% over the last 3 years. Earnings per share has declined by 25%. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings are also forecast to grow by 11% per annum over the same time period. Declared Dividend • Jul 11
Final dividend of JP¥12.00 announced Shareholders will receive a dividend of JP¥12.00. Ex-date: 27th September 2024 Payment date: 4th December 2024 Dividend yield will be 168%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (29% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 2.3% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 36% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Duyuru • Jun 02
Nipro Corporation to Report Q1, 2025 Results on Aug 08, 2024 Nipro Corporation announced that they will report Q1, 2025 results on Aug 08, 2024 Reported Earnings • May 13
Full year 2024 earnings released: EPS: JP¥68.11 (vs JP¥28.05 in FY 2023) Full year 2024 results: EPS: JP¥68.11 (up from JP¥28.05 in FY 2023). Revenue: JP¥586.8b (up 7.6% from FY 2023). Net income: JP¥11.1b (up 143% from FY 2023). Profit margin: 1.9% (up from 0.8% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Duyuru • May 12
Nipro Corporation, Annual General Meeting, Jun 26, 2024 Nipro Corporation, Annual General Meeting, Jun 26, 2024. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥15.00 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 01 July 2024. Payout ratio is a comfortable 29% but the company is not cash flow positive. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (5.0%). Higher than average of industry peers (1.6%). Duyuru • Mar 01
Nipro Corporation to Report Fiscal Year 2024 Results on May 10, 2024 Nipro Corporation announced that they will report fiscal year 2024 results on May 10, 2024 Reported Earnings • Feb 11
Third quarter 2024 earnings released: EPS: JP¥16.54 (vs JP¥4.35 in 3Q 2023) Third quarter 2024 results: EPS: JP¥16.54 (up from JP¥4.35 in 3Q 2023). Revenue: JP¥153.3b (up 5.0% from 3Q 2023). Net income: JP¥2.70b (up 280% from 3Q 2023). Profit margin: 1.8% (up from 0.5% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Duyuru • Nov 29
Nipro Corporation to Report Q3, 2024 Results on Feb 08, 2024 Nipro Corporation announced that they will report Q3, 2024 results on Feb 08, 2024 Reported Earnings • Nov 10
Second quarter 2024 earnings released: EPS: JP¥35.76 (vs JP¥5.99 in 2Q 2023) Second quarter 2024 results: EPS: JP¥35.76 (up from JP¥5.99 in 2Q 2023). Revenue: JP¥145.3b (up 9.7% from 2Q 2023). Net income: JP¥5.83b (up 497% from 2Q 2023). Profit margin: 4.0% (up from 0.7% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Upcoming Dividend • Sep 21
Upcoming dividend of JP¥10.00 per share at 2.0% yield Eligible shareholders must have bought the stock before 28 September 2023. Payment date: 05 December 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 2.0%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (2.0%). Duyuru • Aug 27
Nipro Corporation to Report Q2, 2024 Results on Nov 09, 2023 Nipro Corporation announced that they will report Q2, 2024 results on Nov 09, 2023 New Risk • Aug 10
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. Payout ratio: 106% The company is paying a dividend despite having no free cash flows. Dividend yield: 2.2% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.8% operating cash flow to total debt). Dividend is not well covered by earnings and cash flows. Payout ratio: 106% Paying a dividend despite having no free cash flows. Minor Risk Profit margins are more than 30% lower than last year (0.6% net profit margin). Reported Earnings • Aug 10
First quarter 2024 earnings released: EPS: JP¥25.13 (vs JP¥32.34 in 1Q 2023) First quarter 2024 results: EPS: JP¥25.13 (down from JP¥32.34 in 1Q 2023). Revenue: JP¥140.6b (up 9.9% from 1Q 2023). Net income: JP¥4.10b (down 22% from 1Q 2023). Profit margin: 2.9% (down from 4.1% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Duyuru • May 28
Nipro Corporation to Report Q1, 2024 Results on Aug 09, 2023 Nipro Corporation announced that they will report Q1, 2024 results on Aug 09, 2023 Reported Earnings • May 14
Full year 2023 earnings released: EPS: JP¥28.05 (vs JP¥82.50 in FY 2022) Full year 2023 results: EPS: JP¥28.05 (down from JP¥82.50 in FY 2022). Revenue: JP¥545.2b (up 10% from FY 2022). Net income: JP¥4.57b (down 66% from FY 2022). Profit margin: 0.8% (down from 2.7% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Duyuru • May 13
Nipro Corporation, Annual General Meeting, Jun 28, 2023 Nipro Corporation, Annual General Meeting, Jun 28, 2023. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥8.50 per share at 2.2% yield Eligible shareholders must have bought the stock before 30 March 2023. Payment date: 29 June 2023. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 2.2%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.7%). Reported Earnings • Feb 09
Third quarter 2023 earnings released: EPS: JP¥4.35 (vs JP¥22.90 in 3Q 2022) Third quarter 2023 results: EPS: JP¥4.35 (down from JP¥22.90 in 3Q 2022). Revenue: JP¥146.0b (up 15% from 3Q 2022). Net income: JP¥710.0m (down 81% from 3Q 2022). Profit margin: 0.5% (down from 2.9% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Duyuru • Dec 01
Nipro Corporation to Report Q3, 2023 Results on Feb 08, 2023 Nipro Corporation announced that they will report Q3, 2023 results on Feb 08, 2023 Reported Earnings • Nov 16
Second quarter 2023 earnings released: EPS: JP¥5.99 (vs JP¥24.54 in 2Q 2022) Second quarter 2023 results: EPS: JP¥5.99 (down from JP¥24.54 in 2Q 2022). Revenue: JP¥132.4b (up 6.7% from 2Q 2022). Net income: JP¥977.0m (down 76% from 2Q 2022). Profit margin: 0.7% (down from 3.2% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Reported Earnings • Nov 11
Second quarter 2023 earnings released: EPS: JP¥5.99 (vs JP¥24.54 in 2Q 2022) Second quarter 2023 results: EPS: JP¥5.99 (down from JP¥24.54 in 2Q 2022). Revenue: JP¥132.4b (up 6.7% from 2Q 2022). Net income: JP¥977.0m (down 76% from 2Q 2022). Profit margin: 0.7% (down from 3.2% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥13.50 per share Eligible shareholders must have bought the stock before 29 September 2022. Payment date: 06 December 2022. Payout ratio is a comfortable 29% but the company is not cash flow positive. Trailing yield: 2.9%. Lower than top quartile of German dividend payers (5.1%). Higher than average of industry peers (1.8%). Duyuru • Aug 28
Nipro Corporation to Report Q2, 2023 Results on Nov 09, 2022 Nipro Corporation announced that they will report Q2, 2023 results on Nov 09, 2022 Reported Earnings • Aug 11
First quarter 2023 earnings released: EPS: JP¥32.34 (vs JP¥20.23 in 1Q 2022) First quarter 2023 results: EPS: JP¥32.34 (up from JP¥20.23 in 1Q 2022). Revenue: JP¥127.9b (up 8.4% from 1Q 2022). Net income: JP¥5.28b (up 60% from 1Q 2022). Profit margin: 4.1% (up from 2.8% in 1Q 2022). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 7.3%, compared to a 7.4% growth forecast for the industry in Germany. Reported Earnings • May 13
Full year 2022 earnings released: EPS: JP¥82.50 (vs JP¥87.12 in FY 2021) Full year 2022 results: EPS: JP¥82.50 (down from JP¥87.12 in FY 2021). Revenue: JP¥494.8b (up 8.6% from FY 2021). Net income: JP¥13.5b (down 5.3% from FY 2021). Profit margin: 2.7% (down from 3.1% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 3.7%, compared to a 7.2% growth forecast for the industry in Germany. Duyuru • May 13
Nipro Corporation, Annual General Meeting, Jun 28, 2022 Nipro Corporation, Annual General Meeting, Jun 28, 2022. Duyuru • Apr 08
Nipro Corporation to Report Fiscal Year 2022 Results on May 11, 2022 Nipro Corporation announced that they will report fiscal year 2022 results on May 11, 2022 Upcoming Dividend • Mar 23
Upcoming dividend of JP¥14.50 per share Eligible shareholders must have bought the stock before 30 March 2022. Payment date: 28 June 2022. Payout ratio is a comfortable 35% but the company is not cash flow positive. Trailing yield: 2.8%. Lower than top quartile of German dividend payers (3.6%). Higher than average of industry peers (1.1%). Reported Earnings • Feb 09
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: JP¥22.90 (down from JP¥30.07 in 3Q 2021). Revenue: JP¥127.2b (up 7.1% from 3Q 2021). Net income: JP¥3.74b (down 24% from 3Q 2021). Profit margin: 2.9% (down from 4.1% in 3Q 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 4.8%, compared to a 12% growth forecast for the industry in Germany. Reported Earnings • Nov 10
Second quarter 2022 earnings released: EPS JP¥24.54 (vs JP¥14.99 in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥124.1b (up 9.5% from 2Q 2021). Net income: JP¥4.00b (up 64% from 2Q 2021). Profit margin: 3.2% (up from 2.2% in 2Q 2021). Upcoming Dividend • Sep 22
Upcoming dividend of JP¥14.50 per share Eligible shareholders must have bought the stock before 29 September 2021. Payment date: 07 December 2021. Trailing yield: 2.5%. Lower than top quartile of German dividend payers (3.2%). Higher than average of industry peers (0.8%). Duyuru • Sep 09
Nipro Corporation's Ordinary Shares to Be Deleted from Other OTC Nipro Corporation's Ordinary Shares will be deleted from other OTC effective from September 8, 2021 due to Inactive Security. Reported Earnings • Aug 12
First quarter 2022 earnings released: EPS JP¥20.23 (vs JP¥18.57 in 1Q 2021) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2022 results: Revenue: JP¥118.0b (up 8.3% from 1Q 2021). Net income: JP¥3.30b (up 8.9% from 1Q 2021). Profit margin: 2.8% (in line with 1Q 2021). Reported Earnings • May 14
Full year 2021 earnings released: EPS JP¥87.12 (vs JP¥75.30 loss in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: JP¥455.6b (up 2.9% from FY 2020). Net income: JP¥14.2b (up JP¥26.5b from FY 2020). Profit margin: 3.1% (up from net loss in FY 2020). Duyuru • Mar 06
Nipro Corporation to Report Fiscal Year 2021 Results on May 11, 2021 Nipro Corporation announced that they will report fiscal year 2021 results on May 11, 2021 Is New 90 Day High Low • Feb 18
New 90-day high: €10.90 The company is up 18% from its price of €9.25 on 19 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Medical Equipment industry, which is up 28% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €5.22 per share. Reported Earnings • Feb 10
Third quarter 2021 earnings released: EPS JP¥30.07 (vs JP¥30.49 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: JP¥118.8b (up 4.2% from 3Q 2020). Net income: JP¥4.90b (down 1.4% from 3Q 2020). Profit margin: 4.1% (down from 4.4% in 3Q 2020). Analyst Estimate Surprise Post Earnings • Feb 10
Revenue misses expectations Revenue missed analyst estimates by 1.4%. Over the next year, revenue is forecast to grow 7.6%, compared to a 14% growth forecast for the Medical Equipment industry in Germany. Duyuru • Dec 03
Nipro Corporation to Report Q3, 2021 Results on Feb 08, 2021 Nipro Corporation announced that they will report Q3, 2021 results on Feb 08, 2021 Reported Earnings • Nov 17
Second quarter 2021 earnings released: EPS JP¥14.99 The company reported a poor second quarter result with weaker earnings and profit margins, although revenues were flat. Second quarter 2021 results: Revenue: JP¥113.3b (flat on 2Q 2020). Net income: JP¥2.44b (down 21% from 2Q 2020). Profit margin: 2.2% (down from 2.7% in 2Q 2020). The decrease in margin was driven by higher expenses. Analyst Estimate Surprise Post Earnings • Nov 17
Revenue misses expectations Revenue missed analyst estimates by 5.6%. Over the next year, revenue is forecast to grow 7.2%, compared to a 13% growth forecast for the Medical Equipment industry in Germany. Reported Earnings • Nov 11
Second quarter 2021 earnings released: EPS JP¥14.99 The company reported a poor second quarter result with weaker earnings and profit margins, although revenues were flat. Second quarter 2021 results: Revenue: JP¥113.3b (flat on 2Q 2020). Net income: JP¥2.44b (down 21% from 2Q 2020). Profit margin: 2.2% (down from 2.7% in 2Q 2020). The decrease in margin was driven by higher expenses. Is New 90 Day High Low • Nov 11
New 90-day high: €11.50 The company is up 21% from its price of €9.50 on 13 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €5.26 per share. Is New 90 Day High Low • Oct 27
New 90-day low: €8.85 The company is down 7.0% from its price of €9.50 on 28 July 2020. The German market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €4.45 per share. Duyuru • Aug 23
Nipro Corporation to Report Q2, 2021 Results on Nov 09, 2020 Nipro Corporation announced that they will report Q2, 2021 results on Nov 09, 2020